Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

• Ngā kaituhi matua: Marianne J. Naguib (Author), Amal I. A. Makhlouf (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a p...